Coherus BioSciences Appoints Michael Ryan to its Board of Directors

Strategic Insights -

Coherus BioSciences, Inc. has filed a Current Report with the U.S. Securities and Exchange Commission announcing the appointment of Michael Ryan, Pharm.D., to its Board of Directors. Dr. Ryan brings over four decades of experience in academia and the biopharmaceutical industry, having served in various leadership roles, including Senior Vice President at Bristol-Myers Squibb Company. His background and expertise will be valuable assets to the Company, enhancing its efforts to bring high-value therapeutics to patients.

Key Takeaways:

  • Dr. Michael Ryan, Pharm.D., has been appointed to Coherus BioSciences' Board of Directors, effective July 18, 2023.
  • With four decades of experience in academia and the biopharmaceutical industry, Dr. Ryan brings extensive knowledge and leadership expertise to the Company.
  • He has held various leadership roles, including Senior Vice President at Bristol-Myers Squibb Company and Vice President at Amgen Inc.
  • Dr. Ryan earned his B.A. from the University of California, Los Angeles, and his Pharm.D. from the University of California at San Francisco.
  • He currently serves on the board of the National Pharmaceutical Council and is the Founder and Chief Executive Officer of Koios Enterprises & Consulting.
  • Dr. Ryan will receive an annual cash retainer of $50,000 and an option to purchase 54,000 shares of the Company's common stock under the Company's 2014 Equity Incentive Award Plan.

Statistics:

  • 2026: The year by which Dr. Ryan's term as a director will expire, subject to his earlier death, resignation, or removal.
  • 3 years: The duration over which Dr. Ryan's option to purchase 54,000 shares of the Company's common stock will vest and become exercisable under the Company's 2014 Equity Incentive Award Plan.
  • $50,000: The annual cash retainer Dr. Ryan will receive as a non-employee director of the Company.
  • 27,361,5821: The IRS Employer Identification Number for Coherus BioSciences, Inc.

Sources:

  • UNITED STATES SECURITIES AND EXCHANGE COMMISSION, FORM 8-K, July 20, 2023.
  • Company's Form S-1/A filed with the Securities and Exchange Commission on October 24, 2014 as Exhibit 10.13.